4-acetonyl-2,6-dimethyl pyridine | 70660-28-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-acetonyl-2,6-dimethyl pyridine
• 英文别名: 4-acetonyl-2,6-dimethylpyridine；1-(2,6-dimethyl-pyridin-4-yl)-propan-2-one；1-(2,6-Dimethylpyridin-4-yl)propan-2-one
• CAS: 70660-28-5
• 化学式: C₁₀H₁₃NO
• mdl: MFCD18803041
• 分子量: 163.219
• InChiKey: LCEJYTZYBXTSIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-(2,6-Dimethylpyrylium-4-yl)propan-2-one 、 ammonium hydroxide 以100%的产率得到
  参考文献：
  名称：

  ARNAUD M.; PEDRA A.; ROUSSEL C.; METHGER J., J. ORG. CHEM., 1979, 44 NO 17, 2972-2976

  摘要：

  DOI：

文献信息

• [EN] INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE<br/>[FR] INHIBITEURS DE PHOSPHATIDYLINOSITOL 3-KINASE
  申请人：NOVARTIS AG

  公开号：WO2004096797A1

  公开（公告）日：2004-11-11

  Compounds of formula (I) in free or salt form, wherein R1, R2, R3, and R4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  式(I)中的化合物以自由形式或盐形式存在，其中R1、R2、R3和R4的含义如规范中所示，适用于治疗由磷脂酰肌醇3-激酶介导的疾病。还描述了含有这些化合物的药物组合物以及制备这些化合物的过程。
• Inhibitors of phosphatidylinositol 3-kinase
  申请人：Bruce Ian

  公开号：US20070032487A1

  公开（公告）日：2007-02-08

  Compounds of formula I in free or salt form, wherein R 1 , R 2 , R 3 and R 4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  公式I的化合物以自由或盐形式存在，其中R1、R2、R3和R4的含义如规范中所示，可用于治疗由磷脂酰肌醇3-激酶介导的疾病。还描述了含有这些化合物的制药组合物以及制备这些化合物的过程。
• INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE
  申请人：BRUCE Ian

  公开号：US20110105535A1

  公开（公告）日：2011-05-05

  Compounds of formula I in free or salt form, wherein R 1 , R 2 , R 3 and R 4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  式I的化合物，无论是自由形式还是盐形式，其中R1、R2、R3和R4的含义如说明书所示，可用于治疗由磷脂酰肌醇3-激酶介导的疾病。还描述了含有这些化合物的制药组合物以及制备这些化合物的过程。
• A process for preparing nicotinonitriles and intermediates used therein
  申请人：STERLING DRUG INC.

  公开号：EP0095152A1

  公开（公告）日：1983-11-30

  One aspect of the invention resides in the three step process for preparing cardiotonically active 1,2-dihydro-6-(lower-alkyl)-2-oxo-5-(pyridinyl)nicotinonitriles or 1,2-dihydro-6-(lower-alkyl)-2-oxo-5-(pyridinyl)nicotinamides which comprises reacting a pyridinylmethyl lower-alkyl ketone with tri-(lower-alkyl) orthoformate, acetic anhydride and acetic acid to produce 2-(lower-alkoxy)-1-(pyridinyl)-ethenyl lower-alkyl ketone reacting the latter with cyanoacetamide or malonamide in the presence of a basic condensing agent and neutralizing the reaction mixture, where pyridinyl is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents. Other aspects of the invention reside in the intermediate 2-(lower-alkoxy)-1-(pyridinyl)ethenyl lower-alkyl ketones, their salts and their two step conversion, as described above, to 1,2-dihydro-6-(lower-alkyl)-2-oxo-5-(pyridinyl)-nicotinonitriles or corresponding nicotinamides.

  本发明的一个方面是制备具有生物素活性的 1,2-二氢-6-(低级烷基)-2-氧代-5-(吡啶基)烟酰硝酸酯或 1,2-二氢-6-(低级烷基)-2-氧代-5-(吡啶基)烟酰胺的三步法，包括使吡啶甲基低级烷基酮与三-(低级烷基)原甲酸酯、乙酸酐和乙酸反应，生成 2-(低级烷氧基)-1-(吡啶基)乙烯基低级烷基酮，再使后者与氰乙酰胺或丙二酰酰胺反应、乙酸酐和乙酸反应，生成 2-(低级烷氧基)-1-(吡啶基)-乙烯基低级烷基酮，在碱性缩合剂存在下，使后者与氰乙酰胺或丙二酰胺反应，并中和反应混合物，其中吡啶基是 4-或 3-吡啶基或具有一个或两个低级烷基取代基的 4-或 3-吡啶基。本发明的其他方面在于中间体 2-(低级烷氧基)-1-(吡啶基)乙烯基低级烷基酮、它们的盐和它们的两步转化，如上所述，转化为 1,2-二氢-6-(低级烷基)-2-氧代-5-(吡啶基)-烟酰腈或相应的烟酰胺。
• 2(1H)-pyridinones and preparation, useful as cardiotonics
  申请人：STERLING DRUG INC.

  公开号：EP0109628A1

  公开（公告）日：1984-05-30

  3,4-Dihydro-3-R1-4-R2-5-Q-6-R-2 (1H)-pyridinones (I), where R1 and R2 are each hydrogen or methyl, R is lower-alkyl, and Q is 4 (or 3)-hydroxyphenyl, 4 (or 3)-methoxyphenyl, 4 (or 3)-pyridinyl or 4 (or 3)-pyridinyl having one or two lower-alkyl substituents, or acid-addition salts thereof, as well as the corresponding 3-R1-4-R2-5-Q-6-R-2 (1H)-pyridinones where at least one of R1 and R2 is methyl. The compounds have cardiotonic use when Q is 4 (or 3)-hydroxyphenyl, 4 (or 3)-pyridinyl or 4 (or 3)-pyridinyl having one or two lower-alkyl substituents. Said compounds are prepared from butanenitriles, butanoates, acrylamides or mixtures of alkanones and acetoacetamide, with optional conversion of the 3,4-dihydro compounds obtained to the 3,4-unsaturated compounds by heating with sulfur in an inert solvent and conversion of the methoxyphenyl compounds to the hydroxyphenyl compounds.

  3,4-二氢-3-R1-4-R2-5-Q-6-R-2 (1H)-吡啶酮 (I)，其中 R1 和 R2 分别为氢或甲基，R 为低级烷基，Q 为 4（或 3）-羟基苯基、4（或 3）-甲氧基苯基、4（或 3）-吡啶基或具有一个或两个低级烷基取代基的 4（或 3）-吡啶基，或其酸加成盐、4（或 3）-吡啶基或具有一个或两个低级烷基取代基的 4（或 3）-吡啶基，或其酸加成盐，以及相应的 3-R1-4-R2-5-Q-6-R-2 (1H)-pyridinones （其中 R1 和 R2 中至少有一个是甲基）。当 Q 为 4（或 3）-羟基苯基、4（或 3）-吡啶基或具有一个或两个低级烷基取代基的 4（或 3）-吡啶基时，这些化合物具有强心作用。上述化合物由丁烯腈、丁酸盐、丙烯酰胺或烷酮和乙酰乙酰胺的混合物制备，可选择在惰性溶剂中用硫加热，将得到的 3，4-二氢化物转化为 3，4-不饱和化合物，并将甲氧基苯基化合物转化为羟基苯基化合物。